Table 1 Immunological characteristics pre-BMT, post-BMT and post-CBT

From: Unrelated cord blood transplantation and reduced-intensity conditioning regimen for graft failure in a child with Major Histocompatibility Complex class II deficiency

 

Lymphocyte counts

DR expression (%)

Ig serum levels (mg per 100 ml)

Lymphocyte proliferative responses (c.p.m)

 

Total (cells/μl)

CD3 (%)

CD4 (%)

CD8 (%)

CD19 (%)

CD16+56 (%)

B cells/ monocytes

G

A

M

PHA

Candidin

PPD

Tetanus toxoid

Pre-BMT

7952

49

28

18

22

18

0/0

607

6

63

136236

ND

6064

ND

Post-BMT

 1 month

376

1

ND

ND

<1

93

0/82

ND

ND

ND

ND

ND

ND

ND

 3 months

1334

3

ND

ND

70

20

4/10

901

9

21

ND

ND

ND

ND

 6 months

2112

25

9

11

59

11

2/0

647

7

64

ND

ND

ND

ND

Post-CBT

 1 month

663

12

7

5

<1

72

0/97

ND

ND

ND

ND

ND

ND

ND

 3 months

744

8

6

2

19

46

100/98

993

9

90

ND

ND

ND

ND

 6 months

1320

30

23

5

40

25

100/100

790

96

253

132055

ND

59145

ND

 13 months

2808

39

18

20

18

34

100/100

921

121

195

125978

ND

52850

11606

 31 months

2484

56

26

29

24

8

100/100

1050

75

146

107242

47055

40509

44099

  1. Abbreviations: CBT=cord blood transplantation; ND=not done.
  2. Local reference ranges for age (2–3 years): total lymphocyte counts (cells/μl): 2900−5100; CD3 (%): 62.5–73.0; CD4 (%): 30.0–40.5; CD8 (%): 21.0–24.5; CD19 (%): 14.0–22.0; CD16+56 (%): 9.0–12.0. DR expression on B cells/monocytes (%). Ig levels (mg per 100 ml): IgG: 890±183; IgA: 71.0±37.0; IgM: 61.0±19.0. Lymphocyte proliferative responses (controls) (c.p.m.): PHA: 93–188 × 103; Candidin: 13–36 × 103; PPD: 13–71 × 103; tetanus toxoid: 15–57 × 103.
Back to article page